Solid Earnings, Modest Buyback Fail to Boost Drug Seller 111 Inc.
Profitability is now in focus at online drug company, as it seeks to breathe life into its shares that are down 10% this year Key takeaways: 111’s revenue grew 87%…
RELATED ARTICLES
- Margins ring alarm bells as 160 Health readies IPO
-
Ping An Health pins recovery hopes on new leadership
1833.HK
-
Profits recover at Alibaba Health but prognosis unclear
0241.HK
-
IFlytek hives off health unit to fund AI medical drive
002230.SHE
-
Slowing revenue growth hurts online drug platform YSB
9885.HK
-
Alibaba International records solid growth led by AliExpress
9988.HK BABA.US
-
Akeso marks profit milestone with swift rights issue
9926.HK
Discover hidden China stock gems in our weekly newsletter